168 related articles for article (PubMed ID: 24406245)
1. Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins.
Guerrero-Muñoz MJ; Castillo-Carranza DL; Kayed R
Biochem Pharmacol; 2014 Apr; 88(4):468-78. PubMed ID: 24406245
[TBL] [Abstract][Full Text] [Related]
2. The protective role of plant biophenols in mechanisms of Alzheimer's disease.
Omar SH; Scott CJ; Hamlin AS; Obied HK
J Nutr Biochem; 2017 Sep; 47():1-20. PubMed ID: 28301805
[TBL] [Abstract][Full Text] [Related]
3. Resolving the Atomistic Modes of Anle138b Inhibitory Action on Peptide Oligomer Formation.
Matthes D; Gapsys V; Griesinger C; de Groot BL
ACS Chem Neurosci; 2017 Dec; 8(12):2791-2808. PubMed ID: 28906103
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic species in amyloid-associated diseases: Oligomers or mature fibrils.
Siddiqi MK; Malik S; Majid N; Alam P; Khan RH
Adv Protein Chem Struct Biol; 2019; 118():333-369. PubMed ID: 31928731
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting toxic aggregation of amyloidogenic proteins: a therapeutic strategy for protein misfolding diseases.
Cheng B; Gong H; Xiao H; Petersen RB; Zheng L; Huang K
Biochim Biophys Acta; 2013 Oct; 1830(10):4860-71. PubMed ID: 23820032
[TBL] [Abstract][Full Text] [Related]
6. Disulfide bonds in amyloidogenesis diseases related proteins.
Li Y; Yan J; Zhang X; Huang K
Proteins; 2013 Nov; 81(11):1862-73. PubMed ID: 23760807
[TBL] [Abstract][Full Text] [Related]
7. Modulating self-assembly of amyloidogenic proteins as a therapeutic approach for neurodegenerative diseases: strategies and mechanisms.
Liu T; Bitan G
ChemMedChem; 2012 Mar; 7(3):359-74. PubMed ID: 22323134
[TBL] [Abstract][Full Text] [Related]
8. Generic inhibition of amyloidogenic proteins by two naphthoquinone-tryptophan hybrid molecules.
Scherzer-Attali R; Shaltiel-Karyo R; Adalist YH; Segal D; Gazit E
Proteins; 2012 Aug; 80(8):1962-73. PubMed ID: 22488522
[TBL] [Abstract][Full Text] [Related]
9. The role of amyloidogenic protein oligomerization in neurodegenerative disease.
Lotz GP; Legleiter J
J Mol Med (Berl); 2013 Jun; 91(6):653-64. PubMed ID: 23529761
[TBL] [Abstract][Full Text] [Related]
10. Lipid bilayers significantly modulate cross-fibrillation of two distinct amyloidogenic peptides.
Gal N; Morag A; Kolusheva S; Winter R; Landau M; Jelinek R
J Am Chem Soc; 2013 Sep; 135(36):13582-9. PubMed ID: 23952054
[TBL] [Abstract][Full Text] [Related]
11. Role of oligomers in the amyloidogenesis of primary cutaneous amyloidosis.
Clos AL; Lasagna-Reeves CA; Kelly B; Wagner R; Wilkerson M; Jackson GR; Kayed R
J Am Acad Dermatol; 2011 Nov; 65(5):1023-31. PubMed ID: 21669474
[TBL] [Abstract][Full Text] [Related]
12. Toxic prefibrillar α-synuclein amyloid oligomers adopt a distinctive antiparallel β-sheet structure.
Celej MS; Sarroukh R; Goormaghtigh E; Fidelio GD; Ruysschaert JM; Raussens V
Biochem J; 2012 May; 443(3):719-26. PubMed ID: 22316405
[TBL] [Abstract][Full Text] [Related]
13. Misfolding of amyloidogenic proteins and their interactions with membranes.
Relini A; Marano N; Gliozzi A
Biomolecules; 2013 Dec; 4(1):20-55. PubMed ID: 24970204
[TBL] [Abstract][Full Text] [Related]
14. Baicalein inhibits formation of α-synuclein oligomers within living cells and prevents Aβ peptide fibrillation and oligomerisation.
Lu JH; Ardah MT; Durairajan SS; Liu LF; Xie LX; Fong WF; Hasan MY; Huang JD; El-Agnaf OM; Li M
Chembiochem; 2011 Mar; 12(4):615-24. PubMed ID: 21271629
[TBL] [Abstract][Full Text] [Related]
15. Kinetic profiling of therapeutic strategies for inhibiting the formation of amyloid oligomers.
Michaels TCT; Dear AJ; Cohen SIA; Vendruscolo M; Knowles TPJ
J Chem Phys; 2022 Apr; 156(16):164904. PubMed ID: 35490011
[TBL] [Abstract][Full Text] [Related]
16. Prion protein: structural features and related toxicity.
Hu PP; Huang CZ
Acta Biochim Biophys Sin (Shanghai); 2013 Jun; 45(6):435-41. PubMed ID: 23615535
[TBL] [Abstract][Full Text] [Related]
17. Structural features and cytotoxicity of amyloid oligomers: implications in Alzheimer's disease and other diseases with amyloid deposits.
Stefani M
Prog Neurobiol; 2012 Dec; 99(3):226-45. PubMed ID: 22450705
[TBL] [Abstract][Full Text] [Related]
18. Thermodynamic analysis of structural transitions during GNNQQNY aggregation.
Osborne KL; Bachmann M; Strodel B
Proteins; 2013 Jul; 81(7):1141-55. PubMed ID: 23408546
[TBL] [Abstract][Full Text] [Related]
19. Design of metastable β-sheet oligomers from natively unstructured peptide.
Guerrero-Muñoz MJ; Castillo-Carranza DL; Sengupta U; White MA; Kayed R
ACS Chem Neurosci; 2013 Dec; 4(12):1520-3. PubMed ID: 24106878
[TBL] [Abstract][Full Text] [Related]
20. Disrupting self-assembly and toxicity of amyloidogenic protein oligomers by "molecular tweezers" - from the test tube to animal models.
Attar A; Bitan G
Curr Pharm Des; 2014; 20(15):2469-83. PubMed ID: 23859557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
